Literature DB >> 27981558

Predicting transporter-mediated drug interactions: Commentary on: "Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin" and "Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A".

L Zhang1, A Sparreboom2.   

Abstract

Transporters, expressed in various tissues, govern the absorption, distribution, metabolism, and excretion of drugs, and consequently their inherent safety and efficacy profiles. Drugs may interact with a transporter as a substrate and/or an inhibitor. Understanding transporter-mediated drug-drug interactions (DDIs), in addition to enzyme-mediated DDIs, is an integral part of risk assessment in drug development and regulatory review because the concomitant use of more than one medication in patients is common.
© 2016 ASCPT.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27981558     DOI: 10.1002/cpt.588

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

2.  Evolutionarily Conserved Roles for Blood-Brain Barrier Xenobiotic Transporters in Endogenous Steroid Partitioning and Behavior.

Authors:  Samantha J Hindle; Roeben N Munji; Elena Dolghih; Garrett Gaskins; Souvinh Orng; Hiroshi Ishimoto; Allison Soung; Michael DeSalvo; Toshihiro Kitamoto; Michael J Keiser; Matthew P Jacobson; Richard Daneman; Roland J Bainton
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

3.  Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.

Authors:  Peter Stopfer; Thomas Giessmann; Kathrin Hohl; Sabine Hutzel; Sven Schmidt; Dietmar Gansser; Naoki Ishiguro; Mitchell E Taub; Ashish Sharma; Thomas Ebner; Fabian Müller
Journal:  Br J Clin Pharmacol       Date:  2018-06-21       Impact factor: 4.335

4.  Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.

Authors:  Jim J Xiao; Dorota Nowak; Rodryg Ramlau; Monika Tomaszewska-Kiecana; Piotr J Wysocki; Jeff Isaacson; Jeri Beltman; Eileen Nash; Robert Kaczanowski; Gerhard Arold; Simon Watkins
Journal:  Clin Transl Sci       Date:  2018-12-20       Impact factor: 4.689

5.  Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine.

Authors:  Sabrina T Wiebe; Thomas Giessmann; Kathrin Hohl; Sven Schmidt-Gerets; Edith Hauel; Alen Jambrecina; Kerstin Bader; Naoki Ishiguro; Mitchell E Taub; Ashish Sharma; Thomas Ebner; Gerd Mikus; Martin F Fromm; Fabian Müller; Peter Stopfer
Journal:  Clin Pharmacokinet       Date:  2020-12       Impact factor: 6.447

Review 6.  Nutraceuticals: Transformation of Conventional Foods into Health Promoters/Disease Preventers and Safety Considerations.

Authors:  Mudhi AlAli; Maream Alqubaisy; Mariam Nasser Aljaafari; Asma Obaid AlAli; Laila Baqais; Aidin Molouki; Aisha Abushelaibi; Kok-Song Lai; Swee-Hua Erin Lim
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.